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Background and purpose:Post stroke cognitive assessment can be performed 
using standardised questionnaires designed for family or care-givers. We sought to 
describe the test accuracy of such informant based assessments for diagnosis of 
dementia/multi-domain cognitive impairment in stroke.   
Methods:We performed a systematic review using a sensitive search strategy 
across multidisciplinary electronic databases.  We created summary test accuracy 
metrics and described reporting and quality using STARDdem and QUADAS tools 
respectively.    
Results:From 1432 titles, we included 11 studies. Ten papers used the Informant 
Questionnaire on Cognitive Decline in the Elderly (IQCODE). Four studies described 
IQCODE for diagnosis of post-stroke dementia (n=1197); summary sensitivity:0.81 
(95%CI:0.60-0.93); summary specificty:0.83 (95%CI:0.64-0.93).  Five studies 
described IQCODE as tool for predicting future dementia (n=837); summary 
sensitivity:0.60 (95%CI:0.32-0.83); summary specificity:0.97 (95%CI:0.70-1.00).  All 
papers had issues with at least one aspect of study reporting or quality.  
Conclusions:There is a limited literature on informant cognitive assessments in 
stroke.  IQCODE as a diagnostic tool has test properties similar to other screening 
tools, IQCODE as a prognostic tool is specific but insensitive.  We found no papers 
describing test accuracy of informant tests for diagnosis of pre-stroke cognitive 
decline, few papers on post-stroke dementia and all included papers had issues with 
potential bias. 
  
  
Introduction 
International guidelines recommend that we assess all stroke survivors for cognitive 
disorders, however there is no consensus on the optimal method of assessment.1,2  
A usual first step is to assess with a direct cognitive screening tool such as the 
Montreal Cognitive Assessment (MoCA).  These tools have utility but diagnostic 
accuracy is not perfect.3  In the context of stroke, completion and assessment of 
such tools is complicated by stroke related impairments and physical illness.4,5 
 
An alternative or complementary approach is to seek a history suggestive of 
cognitive problems from family or caregivers.6  Using collateral information sources 
to describe medium to longer term cognitive change is particularly attractive for 
stroke settings as the informant view should be less subject to variation from stroke 
related impairments; should not be biased by educational level or cultural factors and 
offers potential for describing pre-stroke cognition in the acute phase of stroke.7  
Informant assessment can be operationalised using a validated questionnaire such 
as the Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE).8   
 
Taking IQCODE as an exemplar informant assessment, in the original validated 
versions of the scale, it asks a series of questions regarding how cognition and 
functioning have changed over a ten year period.  Individual item scores are collated 
to give a summary score.  Various IQCODE score cut-offs have been described to 
determine clinically important cognitive decline and there is no consensus on the 
optimal cutpoint.7,8  Some have suggested that a high threshold, for example 
IQCODE >3.6, should be used to determine dementia, while a more inclusive 
threshold should be chosen  to define any cognitive impairment.  This approach has 
been used in many important stroke-cognition epidemiological studies.9-11 
 
Other informant assessments include the eight item interview to differentiate ageing 
from dementia (AD-8)12, a shorter questionnaire that seems to have favourable 
properties compared to IQCODE13 , and the Blessed Dementia Scale (BDS);  a 
multidomain assessment that describes change in functional ability, activities of daily 
living and personality.14  Some assessments include an informant component.  For 
example, the GP-Cog is a short screening test designed for use in primary care, 
comprising a direct to patient assessment complemented by six informant questions 
describing change over time.15 None of these informant based tests have been 
specifically designed for use in stroke.  
 
Informant based assessments can be used for three broad purposes in stroke care: 
a)the tools can be used to assess for pre-stroke cognitive decline; b)the tools can be 
used to assist in the process of diagnosing post-stroke cognitive impairment; or c)the 
tools can be used as a prognostic aid, identifying a period of cognitive decline that 
may predict future dementia.  In situation c) the IQCODE is being used to detect 
early cognitive change not sufficient to warrant a label of dementia but that may 
predict risk of future dementia states.(Figure 1) 
 
We sought to collate the published evidence describing test properties of informant 
based cognitive assessments when used in stroke settings.  
 
Methods  
We performed a systematic review of published literature following best practice 
guidance in conduct and reporting.16,17  All aspects of searching, data extraction and 
quality assessment were performed by two independent researchers (AM, NM) with 
access to a third arbitrator (TQ) as needed.  We created a protocol describing the 
search strategy and registered this with the PROSPERO database:PROSPERO 
2014:CRD42014014554 
(www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014014554). 
 
Our primary aim was to describe the accuracy of informant based questionnaires for 
diagnosis of dementia or multi-domain cognitive impairment in stroke-survivors.  
 
Our index test was any standardised informant based cognitive screening 
assessment.  We did not specify how the assessment was performed.  We pre-
specified subgroup analyses based on possible uses of informant assessment: 
a)informant assessment (usually performed in the acute stroke period) for pre-stroke 
cognitive issues; b)informant assessment for contemporaneous assessment of post-
stroke dementia; c)informant assessment (usually performed in the acute period) for 
predicting future cognitive issues (delayed verification).18 
Our target condition was dementia or multi-domain cognitive impairment.  This 
broad classification recognises that a diagnosis of clinically important cognitive 
issues can be made without necessarily assigning a dementia label.  We accepted 
clinical diagnosis of dementia made using any recognised classification system and 
accepted a diagnosis of cognitive impairment based on multi-domain 
neuropsychological assessment. 
Our population of interest was stroke-survivors.  We operated no exclusions based 
on time since stroke or healthcare setting.  In studies with mixed populations we 
included those with greater than 70% stroke survivors.  
 
We developed search terms using a concepts based approach, combined with a 
validated “stroke” filter.  We used Medical Subject Headings and other controlled 
vocabulary.  We included search terms relating to commonly used informant based 
cognitive assessments (IQCODE, AD-8, GP-Cog, Blessed dementia scale) as well 
as generic terms relating to cognitive testing.  We searched across multiple, cross 
disciplinary electronic databases from inception to April 2015.  A collaborator (YF) 
performed a focussed search of Chinese literature databases.  We hand searched 
conference proceedings from international stroke meetings, full search strategy is 
detailed in supplementary materials.   
We screened all titles generated by initial searches for relevance.  Abstracts were 
assessed and potentially eligible studies reviewed as full manuscripts against 
inclusion criteria. We checked reference lists of relevant studies and reviews for 
further titles, repeating the process until no new titles were found.   
 We extracted data to a study specific pro-forma.  For informant scales with various 
cut-points we extracted data for all thresholds available, for studies where IQCODE 
was assessed at varying times post stroke we extracted data for each time point.  
We created tables describing characteristics of included studies, characteristics of 
informant assessments used and characteristics of patients included in studies.   
Where possible, for test accuracy data, we constructed two by two contingency 
tables to allow calculation of sensitivity, specificity and predictive values against a 
dichotomous outcome of cognitive impairment/no cognitive impairment.  Where data 
were not immediately accessible for the paper we contacted lead authors.   
Where data allowed, we calculated sensitivity, specificity, and corresponding 95% 
confidence intervals (95% CI) on test accuracy forest plots (RevMan 5.1, Cochrane 
Collaboration) and pooled test accuracy data using the bivariate approach with a 
bespoke macro.19  We did not formally assess publication bias, as standard tests 
such as “funnel plots” are not appropriate and there is no consensus on the optimal 
measure of such bias in test accuracy review.  
 
We assessed risk of bias and generalizability using the Quality Assessment of 
Diagnostic Accuracy Studies tool (QUADAS-2)20 tool.  QUADAS-2 assesses 
domains of patient selection; application of index test; application of reference 
standard and patient flow/timing.  We previously created and validated a series of 
anchoring statements for QUADAS-2 for test accuracy work with a dementia 
reference standard.21  We assessed quality of reporting using the dementia specific 
extension to the Standards for Reporting of Diagnostic Accuracy STARDdem16 tool.  
STARDdem assesses reporting of key items for dementia test accuracy work across 
the introduction, methods, results, discussion sections of a manuscript. Full details of 
scoring criteria are given in supplementary materials.   
 
Results 
After deduplication, we screened 1,432 titles.(Figure 2) Following assessment of 
abstract or full paper we included 11 studies in our review.22-32  Ten studies detailed 
the IQCODE, including n=1994 participants (n=465 [23%] with dementia).22-31  One 
study detailed the BDS, including n=220 patients with data (n=93 [42%] with 
cognitive impairment).32   
 
There was substantial study heterogeneity.  Across the included studies informant 
assessments were used for a variety of purposes across various settings, with 
varying cut-points.(Table 1 and supplementary materials)  The reporting around 
application of IQCODE was poor for several studies and it was not clear if a 
validated form of the questionnaire was used (n=3 studies); the time period over 
which IQCODE retrospective review was performed (n=4 studies) or which 
informants were used (n=3 studies).(supplementary materials)  The generalisability 
of the patient populations used to assess IQCODE was variable.  Where data were 
reported there were substantial baseline exclusions and included patient were young 
with relatively mild stroke.(supplementary materials) 
 
Pre-stroke dementia: No study described test properties of assessments for the 
diagnosis of pre-stroke cognitive decline versus a reference standard for clinical 
diagnosis.(Table 1)   
Contemporaneous diagnosis of post-stroke dementia: For IQCODE (4 papers, 
n=1197 participants)23-26 summary test metrics were sensitivity:0.81 (95%CI:0.60-
0.93; range:0.33-0.88) and specificity:0.82 (95%CI:0.64-0.92; range:0.63-
0.98).(Figure 3 and Table 2) 
Delayed verification/prognosis: For IQCODE (5 papers, n=837 participants)26-30 
summary test metrics were sensitivity:0.60 (95%CI:0.32-0.83; range:0.25-0.93) and 
specificity:0.97 (95%CI:0.70-1.00; range:0.66-1.00).(Figure 3 and Table 2)  Where 
the approach to analysis was described, most papers assessed cognitive decline in 
the immediate period post-stroke and described the association with longer term 
dementia diagnosis.(supplementary materials)   
The BDS had sensitivity 60% and specificity 76% (PPV:0.73; NPV:0.64) for 
diagnosis of any memory related impairment.32 
 
No papers scored “low risk of bias” on all QUADAS-2 items. Areas of concern were 
around patient flow/loss to follow up (with substantial loss of IQCODE data, where 
reported) and the application of the IQCODE (risk of incorporation bias and using 
IQCODE in a non-validated way).(Figure 4 and supplementary materials)  There 
were issues with reporting; no papers reported all details as recommended in 
STARDdem, particular problems were around reporting of results and details of 
statistical analyses.   For example, two papers described blinding between those 
applying the informant test and those performing clinical assessment; one paper 
described how missing or indeterminate results were handled in statistical analyses 
and no papers described test reliability or reproducibility.(supplementary materials) 
 
Discussion  
Although there are many informant based cognitive assessment tools available6, few 
have been validated in stroke.  Only the IQCODE had more than one paper 
describing stroke test properties and there was substantial heterogeneity in test 
accuracy reported.  Across the included studies there were also issues with study 
quality and reporting and so we need to be cautious in the interpretation of these 
data.   
 
Accepting these caveats we can draw some conclusions on properties of IQCODE in 
stroke.  Across all studies IQCODE showed a pattern of specificity but high false 
negative rate.  IQCODE for assessing post-stroke dementia had reasonable test 
accuracy.  In practice, IQCODE or similar would often be used along with another 
direct to patient cognitive test, however we found no studies validating this approach.   
 
IQCODE early after stroke has been used as a tool to predict future dementia.  We 
accept that the use of retrospective assessment to predict future dementia is counter 
intuitive and it is interesting that a number of papers used this approach.  When used 
for this purpose a positive IQCODE is likely to be associated with dementia but many 
that develop dementia will have an initial IQCODE assessment below the threshold 
set for this purpose (specific but lacks sensitivity).  This pattern of trade-off between 
sensitivity and specify changed when IQCODE was used at longer periods after the 
stroke event.  The interpretation of these data is complicated by limited reporting 
around how the IQCODE was applied and this was apparent in our assessments of 
quality and reporting.   
 
Informant assessments such as IQCODE are often used in practice and in research 
to assess pre-stroke cognition.  There are many excellent examples of describing 
pre-stroke cognition using IQCODE.33,34  While this approach makes intuitive sense, 
we found no published reports that validate the test accuracy of this use of IQCODE.     
 
Our data adds to the literature on test properties of brief cognitive assessments in 
stroke.  The accuracy of IQCODE for diagnosis of post stroke dementia was similar 
to summary metrics for other direct to patient cognitive assessments in stroke.1  
There is no ideal cognitive test for use with stroke populations.  Choice of test needs 
to consider accuracy but also the purpose of the testing and issues such as 
feasibility.35  Although based on a self-completion questionnaire, we should not 
assume feasibility and acceptability of IQCODE.  We note the high non-completion 
rates of IQCODE in many of these studies, reminding us that IQCODE requires a 
suitable informant and that the informant has to understand and complete the 
questionnaire.  There are some data in non-stroke settings to suggest that 
availability of an informant when accessing healthcare is associated with abnormal 
cognition.36  IQCODE and other informant assessments may be complicated where a 
spouse or caregiver also has cognitive issues.  In some centres, informants have a 
brief cognitive screen to assess their suitability to complete questionnaires such as 
IQCODE.  It is unfortunate that no assessment of informants was made in any of the 
papers included in this review. 
 
Interpreting our data on IQCODE we should remember that IQCODE was developed 
for assessing dementia in community dwelling older adults and there are many 
reasons why the questionnaire may not work well in stroke.  Certain IQCODE items 
may be difficult to score in the context of stroke, for example the IQCODE question 
on using gadgets may give false positives for stroke-survivors with physical disability 
but no cognitive deficit.  The memory based focus of IQCODE may be less 
appropriate in vascular cognitive impairment syndromes, where executive function 
deficits may predominate.  Finally, early physical recovery that can occur following 
stroke may be wrongly scored as positive cognitive change on IQCODE, a situation 
that would not be seen in Alzheimer’s disease.      
 
A particular issue in our “quality” assessment was around the application of the 
IQCODE.  An issue with IQCODE is that it may be used in practice to inform the 
diagnostic formulation.  There were included papers that risked such incorporation 
bias, comparing IQCODE to a reference standard of clinical diagnosis where the 
clinical diagnosis included IQCODE data.  The generalisability of included 
populations was limited and certain studies excluded exactly those patients where 
IQCODE may be useful (aphasia, coma).  Problems of selection bias in studies of 
post stroke cognition are not unique to IQCODE.4   
 It is interesting to note how the use of IQCODE in stroke deviates from that 
described in the original IQCODE derivation and validation work.  The original 
IQCODE was designed to describe cognitive decline over a ten year period.  This 
approach is better suited to assess a progressive neurodegenerative condition such 
as Alzheimer’s disease, rather than an acute event such as stroke.  In practice, 
assessors may use the IQCODE questions to explore cognitive change since a 
stroke event which may not necessarily be ten years past.  Some papers also use 
repeated IQCODE assessments at endpoints.  Altering the IQCODE in this way is 
not validated and so many papers were scored as potential risk of bias/poor external 
validity due to this issue.  Where IQCODE covers a ten year period that includes a 
stroke event, the IQCODE result gives information on general cognitive decline but 
does not tell us that this decline relates purely to stroke.  These concerns should not 
dissuade clinicians and researchers from using informant based assessments but 
suggest that more work is needed around tailoring informant assessments to fit post 
stroke populations.  The data from our review do not allow us to give definitive 
guidance on when IQCODE should be applied.  To avoid recall biases, we would 
suggest that informant assessment for pre-stroke dementia be performed close to 
the stroke event but with sufficient time to allow the informant to adjust to the 
diagnosis of stroke in their relative or friend.   
 
Strengths of our study were the comprehensive literature search, including access to 
non-English language electronic databases.  We acknowledge the between study 
heterogeneity and issues with risk of bias, generalisability and reporting.  To allow for 
data synthesis we accepted any clinical diagnosis of a cognitive syndrome as our 
reference standard.  As a result of this, the summary estimates we offer are 
illustrative and should not be interpreted as definitive test accuracy metrics.  Number 
of included papers was too small to allow meaningful sensitivity analyses around 
these issues. 
 
 
Our data do not allow us to make a definitive statement on the “best” available 
informant assessment.  While there are major limitations to the use of IQCODE, 
using this tool is probably better than no informant assessment at all.  An important 
finding is the clinical-research gap around this form of cognitive testing.  Future 
studies should consider the test properties of IQCODE and the other available 
informant assessments.  A focus on use of informant assessments for pre-stroke 
cognitive states and on combining informant questionnaires with other direct to 
patient tests is needed. 
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Figure 1.Describing three differing approaches to informant assessment in stroke 
care 
 
Figure describes potential uses of informant questionnaires for cognitive assessment 
in stroke.  IQCODE can be used in the acute stroke period to assess for pre-stroke 
cognitive decline or at any period post-stroke to assess for cognitive impairment at 
that time.  IQCODE has also been used to predict those likely to have a later 
dementia diagnosis. 
 
 
 
Figure 2.Flow diagram detailing search strategy and results   
 
  
Figure 3.Forest plots of sensitivity and specificity in relation to IQCODE for diagnosis 
of dementia   
  
  
Forest plots detail IQCODE for contemporaneous diagnosis (top) and IQCODE for 
“prognosis” (bottom).  For the delayed verification studies (prognosis), where data 
were presented at varying time-points we used one year data or closest.  
TP,FP,FN,TN:true positive,false positive,false negative, true negative 
 
  
Figure 4.QUADAS-2 based assessment of bias and applicability 
  
 Explanations of QUADAS-2 domains are offered in supplementary materials  
  
 Table 1.Summary of included studies 
NPB=Neuropsychological battery, GCF=General Cognitive Factor; 
RBANS=Repeatable Battery for the assessment of neuropsychological status; 
DSM=Diagnostic and Statistical Manual; ICD=International Classification of Disease;  
VCI-HS=vascular cognitive impairment harmonisation standards 
ASU=Acute Stroke unit; Rehab=Rehabilitation setting; N/A=not 
available(unknown/not reported 
*Data from extended abstract and parent studies  
Study 
Setting 
(recruitment) 
Timing of 
diagnosis 
(post stroke) 
Index 
test(s) 
Diagnostic 
test(S) Diagnostic test rater 
Informant scale for contemporaneous diagnosis of dementia 
Jung*  
201523 Community 3 month 
IQCODE 
(Korean) VCI-HS Neuropsychologist 
Tang  
200324 ASU 3 month 
IQCODE 
(Chinese) DSM-IV Stroke neurologist 
Starr  
200022 Community 4.3 years IQCODE  NPB Neuropsychologist 
Srikanth 
200625 Community 3 month IQCODE16 DSM IV Neuropsychologist 
Narasimhalu 200826 N/A N/A IQCODE16 (Chinese) DSM IV Adjudication panel 
Informant scale for diagnosis of pre-stroke dementia 
No relevant papers found on systematic literature review   
Informant scale for prospective (delayed verification) diagnosis of dementia  
Henon  
200127 ASU 
6, 12,24,36 
months 
IQCODE 
(French) ICD-10 Adjudication panel 
Klimkowicz 200528 ASU 3 month IQCODE  (Polish) DSM-IV Stroke neurologist 
Serrano  
200730 ASU 
3, 12, 24 
month 
IQCODE16 
(Spanish) 
DSM 
NPB Neurologist 
Wagle  
201031 Rehab 13/12 
IQCODE 
(Danish) RBANS N/A 
Selim  
200929 ASU <18/12 
IQCODE 
(Egyptian) ICD 10 Neurologist 
Table 2.Results of included studies 
 
sens=sensitivity; spec=specificity; PPV/NPV=positive/negative predictive value 
IQCODE thresholds are given as presented in primary paper (some are average 
score and some are raw-score); where more than one IQCODE threshold employed, 
the primary cutpoint is described. 
 
 
Study "n" included "n" (%) with dementia 
“n” (%) not 
completing 
IQCODE 
Index test 
(threshold) Summary Results 
Informant scale for contemporaneous diagnosis of dementia 
Jung 201523 353 45 ? IQCODE ≥3.6 Sens 45% Spec 96%  PPV:0.63 NPV:0.92 
Tang 200324 189 24 108 (36%) IQCODE ≥ 3.40 Sens:33% Spec:98% PPV:0.34 NPV:0.98 
Starr 200022 35 N/A 14 (29%) N/A Correlation with GCF (r=-0.42, p=0.016) 
Srikanth 200625 79 8 20 (20%) IQCODE ≥ 3.30 Sens: 88%; Spec:63% PPV:0.21 NPV:0.98 
Narasimhalu 200826 576 169 ? IQCODE > 3.38 Sens:86% Spec:78%  PPV:0.62 NPV:0.93 
Informant scale for diagnosis of pre-stroke dementia 
No relevant papers found on systematic literature review   
Informant scale for prospective (delayed verification) diagnosis of dementia 
Henon 200127 127 at 6/12 104 at 36/12 36 at 36/12 56 (22%) IQCODE ≥ 78 
Sens:30%; Spec:100% 
(6/12)* 
PPV:1.0 
NPV:0.74 
Klimkowicz 200528 142 26 ? IQCODE ≥ 104 Sens: 66%; Spec:100% PPV:1.0 NPV:0.92 
Serrano 200730 167 at 12/12 142 at 24/12 
44 at 12/12 
33 at 24/12 33 (10%) IQCODE > 3.35 
 
Sens:93% Spec:81% 
(12/12) 
PPV:0.55 
NPV:0.98 
Wagle 201031 104 52 8 (8%) IQCODE > 3.44 Sens:25% Spec:92%  PPV:0.76 NPV:0.55 
Selim 200929 66 28 8 (9%) IQCODE ≥ 78 Sens:69% Spec:66% PPV:0.39 NPV:0.87 
